Personalis, Inc. 8-K
Research Summary
AI-generated summary
Personalis, Inc. Announces Medicare Coverage Expansion for NeXT Personal Test
What Happened
Personalis, Inc. announced in an 8-K filed May 20, 2026 that on May 19, 2026 the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostics Program expanded Medicare coverage for the company's ultrasensitive NeXT Personal® test. The coverage expansion applies to monitoring treatment response to neoadjuvant therapy (NAT) in patients diagnosed with Stage II–III Triple-Negative Breast Cancer (TNBC) or HER2-positive (HER2+) breast cancer.
Key Details
- Filing: Form 8-K (Item 8.01 Other Events) filed May 20, 2026.
- CMS action date: May 19, 2026 (Molecular Diagnostics Program decision).
- Test: NeXT Personal® ultrasensitive assay.
- New covered use: Monitoring treatment response to neoadjuvant therapy in Stage II–III TNBC and HER2+ breast cancer patients.
Why It Matters
Medicare coverage decisions determine reimbursement pathways and influence patient access and clinical adoption. This CMS expansion formally extends Medicare coverage for a specific clinical use of Personalis’s NeXT Personal test, which is a material commercial and regulatory development disclosed to investors.
Loading document...